Evidence map›Paper›PMID 42247518›Full record

ArticleScience advances2026

Uncovering functional variants using a high-efficiency PE3-based screening platform.

Shisheng Huang, Wanyu Tao, Xiangyang Li, Junfan Guo, Yu Zhang, Guanglei Li, Pengfei Zhang, Guiquan Zhang, Gaoyang Li, Gaofeng Fan and 2 more

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shisheng HuangThe Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu 213003, China.ORCID 0000-0002-7869-0043
Wanyu TaoSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.ORCID 0009-0009-2999-3097
Xiangyang LiThe Key Laboratory of Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.ORCID 0009-0005-8735-9263
Junfan GuoSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Yu ZhangSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.ORCID 0000-0001-9033-5012
Guanglei LiSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Pengfei ZhangThe Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu 213003, China.
Guiquan ZhangThe Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu 213003, China.
Gaoyang LiThe Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu 213003, China.ORCID 0000-0001-6837-0719
Gaofeng FanSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.ORCID 0000-0002-6729-2867
Shang-Min ZhangSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.ORCID 0000-0001-9043-0116
Xingxu HuangSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.ORCID 0000-0001-8934-1247

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prime editing (PE) enables precise nucleotide changes but has limited utility in high-throughput functional screening due to low editing efficiency. Here, we developed EvoPRIME, a PE3-based screening platform that integrates Csy4-mediated processing of Pol II-driven guide RNAs with a fluorescence-based enrichment strategy. EvoPRIME achieves comparable efficiency to state-of-the-art prime editing systems without requiring mismatch repair (MMR) suppression. We validated the performance of EvoPRIME through a loss-of-function (LOF) dropout screen targeting essential genes, which showed improved sensitivity and reproducibility, and a gain-of-function (GOF) saturation mutagenesis screen of the EGFR tyrosine kinase domain under osimertinib selection, which identified both known and uncharacterized resistance-conferring mutations. Leveraging EvoPRIME, we further conducted a high-throughput screen that functionally assesses both gain- and loss-of-phosphorylation (GOP and LOP) mutations. Among the hits, GAB1 S419E emerged as a phosphomimetic mutation that activates AKT signaling and confers osimertinib resistance. These studies establish EvoPRIME as a versatile platform for uncovering functional variants.

Indexed as

High-Throughput Screening AssaysAcrylamidesAdaptor Proteins, Signal TransducingAniline CompoundsErbB ReceptorsHumansIndolesMutationPhosphorylationPyrimidinesAcrylamidesAdaptor Proteins, Signal TransducingAniline CompoundsErbB ReceptorsIndolesosimertinibPyrimidines

Identifiers

PMID42247518
PMCPMC13240188

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.